- Home
- CMPX vs SKYE Comparison
CMPX vs SKYE Comparison
Compare CMPX & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMPX
- SKYE
- Stock Information
- Founded
- CMPX 2014
- SKYE 2012
- Country
- CMPX United States
- SKYE United States
- Employees
- CMPX N/A
- SKYE N/A
- Industry
- CMPX Biotechnology: Pharmaceutical Preparations
- SKYE Biotechnology: Pharmaceutical Preparations
- Sector
- CMPX Health Care
- SKYE Health Care
- Exchange
- CMPX Nasdaq
- SKYE Nasdaq
- Market Cap
- CMPX 291.8M
- SKYE 115.9M
- IPO Year
- CMPX N/A
- SKYE N/A
- Fundamental
- Price
- CMPX $2.65
- SKYE $3.98
- Analyst Decision
- CMPX Strong Buy
- SKYE Buy
- Analyst Count
- CMPX 9
- SKYE 6
- Target Price
- CMPX $12.67
- SKYE $16.60
- AVG Volume (30 Days)
- CMPX 816.0K
- SKYE 2.2M
- Earning Date
- CMPX 08-11-2025
- SKYE 08-08-2025
- Dividend Yield
- CMPX N/A
- SKYE N/A
- EPS Growth
- CMPX N/A
- SKYE N/A
- EPS
- CMPX N/A
- SKYE N/A
- Revenue
- CMPX $850,000.00
- SKYE N/A
- Revenue This Year
- CMPX N/A
- SKYE N/A
- Revenue Next Year
- CMPX N/A
- SKYE N/A
- P/E Ratio
- CMPX N/A
- SKYE N/A
- Revenue Growth
- CMPX N/A
- SKYE N/A
- 52 Week Low
- CMPX $0.87
- SKYE $1.14
- 52 Week High
- CMPX $4.08
- SKYE $7.47
- Technical
- Relative Strength Index (RSI)
- CMPX 64.52
- SKYE 60.88
- Support Level
- CMPX $2.62
- SKYE $3.65
- Resistance Level
- CMPX $2.87
- SKYE $4.75
- Average True Range (ATR)
- CMPX 0.16
- SKYE 0.71
- MACD
- CMPX 0.00
- SKYE 0.00
- Stochastic Oscillator
- CMPX 81.03
- SKYE 48.55
About CMPX Compass Therapeutics Inc.
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.